Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Elplat, Elaspol Generics to Join NHI Price List on Dec. 12
December 11, 2014
- Wholesalers’ Negative Primary Margin on Sales Widens Slightly in First Half of FY2014: Ryukaikon
December 11, 2014
- Ryukaikon Members Hail High Price Settlements, but Fret over Fallout from Penalty Fee Cuts
December 11, 2014
- Annual NHI Price Cuts Draw Fire from All Sides at Ryukaikon Council
December 10, 2014
- Eculizumab, Bosentan Designated as Orphan Drugs
December 10, 2014
- Japan NIH to Have Drug Discovery Support Unit
December 9, 2014
- Paclitaxel OK’ed for External Review under Fast-Track Senshin-Iryo Scheme for Cancer Drugs
December 8, 2014
- Five SGLT-2 Inhibitors Undergoing Evaluation for Risk of Dehydration: PMDA
December 8, 2014
- Fee Cut Rule Needs Review before Debate on Annual NHI Price Revisions: MHLW Exec
December 4, 2014
- LDP Members Share Various Opinions on Social Security Issues
December 4, 2014
- Council Approves Subsidies for Retreatment with 3-Drug Combination Therapies Using Protease Inhibitors Other than Simeprevir
December 4, 2014
- ICH Makes Progress Toward Greater Inclusivity, Agrees to Establish Assembly at November Meeting in Lisbon
December 4, 2014
- Pharma Industry Girding for Post-Election Lobbying on R&D Tax Credit
December 3, 2014
- Kyowa Kirin’s Poteligeo to Receive Additional Indication for Incipient Untreated ATL, Will Be Added to mLSG15 Therapy
December 2, 2014
- Editor’s Pick: Five Healthcare News Headlines for Nov. 17 - 28
December 1, 2014
- PAFSC’s Second Committee Backs Approval of Novartis’s Secukinumab
December 1, 2014
- Japan’s 1st Orphan Regenerative Medicine Status Given to Skin-Derived Cell Sheet
December 1, 2014
- 13 APIs/23 Products Including Remicade Biosimilar Added to NHI Price List
November 28, 2014
- MHLW Warns of Hyperbilirubinemia in Patients on Sovriad
November 27, 2014
- Panel Gives Green Light to Draft Report Calling for Legal Regulations for Clinical Research
November 27, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…